Evonetix unveils new branding to align with its vision for gene-length DNA synthesis

EVONETIX LTD (‘Evonetix’), the Company developing semiconductor scale technology to improve access to gene synthesis, today announces the introduction of new branding to align with its vision to ‘Redefine possible’ through the development and commercialization of its benchtop semiconductor gene synthesis platform. The rebrand follows a period of significant milestones, including external evaluation of Evonetix’s chip-synthesized DNA.

Evonetix’s gene synthesis platform combines its patented semiconductor chip design and thermally controlled synthesis chemistry, with proprietary on-chip assembly and error correction, enabling accurate, gene-length DNA synthesis at the benchtop of any lab.

Access to gene-length DNA will be transformative for engineering biology research, with applications across medicine, agriculture, chemistry, materials and more. The platform will bypass the intrinsic limitations of scaling existing technologies to deliver accurate gene-length DNA through a decentralized approach.

The Company has seen a period of significant progress in the development of its benchtop DNA synthesis platform over the last twelve months, including the delivery of its chip-synthesized DNA to the University of Cambridge for evaluation.

“Our new identity represents the revolutionary work we are doing to deliver gene synthesis at the speed and scale required to enable scientists to address humanity’s greatest challenges. The new branding reflects the passion and expertise of our team as we prepare to communicate our product offering to the wider scientific community and our vision to ‘Redefine possible’.”

Colin McCracken, Chief Executive Officer at Evonetix 

“This is an exciting step for Evonetix. Our groundbreaking semiconductor technology reimagines gene synthesis, putting control directly into the hands of end-users and enabling the assembly of gene-length DNA at speed and scale. We are breaking through a multitude of technological barriers, developing a fundamentally different approach to gene synthesis to enable the engineering biology revolution. Our new branding reflects this bold ambition.”

Mike Daniels, VP Product at Evonetix

For more news from Evonetix, please visit: https://www.evonetix.com/news/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evonetix. (2023, October 02). Evonetix unveils new branding to align with its vision for gene-length DNA synthesis. News-Medical. Retrieved on October 15, 2024 from https://www.news-medical.net/news/20231002/Evonetix-unveils-new-branding-to-align-with-its-vision-for-gene-length-DNA-synthesis.aspx.

  • MLA

    Evonetix. "Evonetix unveils new branding to align with its vision for gene-length DNA synthesis". News-Medical. 15 October 2024. <https://www.news-medical.net/news/20231002/Evonetix-unveils-new-branding-to-align-with-its-vision-for-gene-length-DNA-synthesis.aspx>.

  • Chicago

    Evonetix. "Evonetix unveils new branding to align with its vision for gene-length DNA synthesis". News-Medical. https://www.news-medical.net/news/20231002/Evonetix-unveils-new-branding-to-align-with-its-vision-for-gene-length-DNA-synthesis.aspx. (accessed October 15, 2024).

  • Harvard

    Evonetix. 2023. Evonetix unveils new branding to align with its vision for gene-length DNA synthesis. News-Medical, viewed 15 October 2024, https://www.news-medical.net/news/20231002/Evonetix-unveils-new-branding-to-align-with-its-vision-for-gene-length-DNA-synthesis.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Evonetix appoints Colin McCracken as Chief Executive Officer